v3.26.1
Segment Information - Reportable Segment Information (Detail) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating Income (Loss) [Abstract]    
Net sales $ 2,741 $ 2,843
Cost of sales (1,723) (1,808)
Research and development expenses (166) (164)
Selling and administrative expenses (427) (461)
Depreciation & Amortization (246) (236)
Interest Expense (44) (71)
Other Expense, net (13) (20)
Restructuring and other charges (6) (17)
Impairment of goodwill 0 (1,153)
Losses on Business Disposals (7) 0
Divestiture and integration costs (24) (51)
Strategic initiative costs (9) (8)
Regulatory costs (10) (11)
Other costs   (5)
Income (loss) before taxes 209 (994)
Taste    
Operating Income (Loss) [Abstract]    
Restructuring and other charges (2) (2)
Food Ingredients    
Operating Income (Loss) [Abstract]    
Restructuring and other charges (2) (3)
Health & Biosciences    
Operating Income (Loss) [Abstract]    
Restructuring and other charges (2) (3)
Scent    
Operating Income (Loss) [Abstract]    
Restructuring and other charges 0 (9)
Operating Segments    
Operating Income (Loss) [Abstract]    
Net sales 2,741 2,843
Adjusted Operating EBITDA 568 578
Operating Segments | Taste    
Operating Income (Loss) [Abstract]    
Net sales 656 627
Cost of sales (375) (377)
Research and development expenses (43) (40)
Selling and administrative expenses (101) (94)
Depreciation expense add-back 16 15
Adjusted Operating EBITDA 153 131
Operating Segments | Food Ingredients    
Operating Income (Loss) [Abstract]    
Net sales 839 796
Cost of sales (646) (609)
Research and development expenses (14) (12)
Selling and administrative expenses (99) (92)
Depreciation expense add-back (34) (28)
Adjusted Operating EBITDA 114 111
Operating Segments | Health & Biosciences    
Operating Income (Loss) [Abstract]    
Net sales 595 540
Cost of sales (327) (298)
Research and development expenses (55) (52)
Selling and administrative expenses (92) (81)
Depreciation expense add-back 32 29
Adjusted Operating EBITDA 153 138
Operating Segments | Scent    
Operating Income (Loss) [Abstract]    
Net sales 651 614
Cost of sales (375) (344)
Research and development expenses (54) (55)
Selling and administrative expenses (92) (86)
Depreciation expense add-back (18) (15)
Adjusted Operating EBITDA $ 148 144
Operating Segments | Pharma Solutions    
Operating Income (Loss) [Abstract]    
Net sales   266
Cost of sales   (180)
Research and development expenses   (5)
Selling and administrative expenses   (32)
Depreciation expense add-back   (5)
Adjusted Operating EBITDA   $ 54